Potential Signal Transduction Regulation by HDL of the β2-Adrenergic Receptor Pathway. Implications in Selected Pathological Situations

Archives of Medical Research

Volumn 46, Issue 5, 2015, Pages 361-371

  Niesor, Eric J ^a,b   Benghozi, Renée ^a,c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Pre beta1 Consulting   (Switzerland)

^c Cerenis Therapeutics   (France)

Author keywords

ABCA1; Adenylyl cyclase; Caveolae; HDL; Signal transduction; 2 adrenergic receptor

Indexed keywords

ABC TRANSPORTER A1; ADENYLATE CYCLASE; ADENYLATE CYCLASE 9; APOLIPOPROTEIN A1; BETA 2 ADRENERGIC RECEPTOR; CATECHOLAMINE; CHOLESTEROL; DALCETRAPIB; G PROTEIN COUPLED RECEPTOR; HIGH DENSITY LIPOPROTEIN; INSULIN; ION CHANNEL; UNCLASSIFIED DRUG; ABC TRANSPORTER; CARRIER PROTEIN; MEMBRANE PROTEIN;

ADIPOSE TISSUE; ASTHMA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAVEOLA; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; GENETIC SUSCEPTIBILITY; HEART MUSCLE CELL; HUMAN; LIPID RAFT; MALARIA; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PHYSICAL CHEMISTRY; REVIEW; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR SMOOTH MUSCLE CELL; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADENYLATE CYCLASE; APOLIPOPROTEIN A-I; ATP-BINDING CASSETTE TRANSPORTERS; CARDIOVASCULAR DISEASES; CARRIER PROTEINS; CAVEOLAE; CHOLESTEROL; HUMANS; LIPOPROTEINS, HDL; MEMBRANE PROTEINS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION;

EID: 84938053438     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2015.05.008     Document Type: Review

References (87)

1. Rader D.J., Alexander E.T., Weibel G.L., et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009, 50(Suppl):S189-S194.
2. Khera A.V., Cuchel M., de la Llera-Loya M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011, 364:127-135.
3. Fielding C.J., Fielding P.E. Membrane cholesterol and the regulation of signal transduction. Biochem Soc Trans 2004, 32:65-69.
4. Tuteja S., Rader D.J. High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm. Clin Pharmacol Ther 2014, 96:48-56.
5. Niesor E.J. Will lipidation of ApoA1 through interaction with ABCA1 at the intestinal level affect the protective functions of HDL?. Biology (Basel) 2015, 4:17-38.
6. Yvan-Charvet L., Kling J., Pagler T., et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010, 30:1430-1438.
7. Bellanger N., Julia Z., Villard E.F., et al. Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy. Atherosclerosis 2012, 221:160-168.
8. Tardy C., Goffinet M., Boubekeur N., et al. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis 2014, 232:110-118.
9. Ray K.K., Ditmarsch M., Kallend D., et al. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. Eur Heart J 2014, 35:1792-1800.
10. Tardif J.C., Rheaume E., Lemieux Perreault L.P., et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet 2015, 8:372-382.
11. Okamoto H., Yonemori F., Wakitani K., et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000, 406:203-207.
12. Niesor E.J., Magg C., Ogawa N., et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J Lipid Res 2010, 51:3443-3454.
13. Maugeais C., Perez A., von der M.E., et al. Evidence for a role of CETP in HDL remodeling and cholesterol efflux: role of cysteine 13 of CETP. Biochim Biophys Acta 2013, 1831:1644-1650.
14. Schwartz G.G., Olsson A.G., Abt M., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012, 367:2089-2099.
15. Slotte J.P. Biological functions of sphingomyelins. Prog Lipid Res 2013, 52:424-437.
16. Murata M., Peranen J., Schreiner R., et al. VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci U S A 1995, 92:10339-10343.
17. Bist A., Fielding P.E., Fielding C.J. Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol. Proc Natl Acad Sci U S A 1997, 94:10693-10698.
18. Rothberg K.G., Heuser J.E., Donzell W.C., et al. Caveolin, a protein component of caveolae membrane coats. Cell 1992, 68:673-682.
19. Hailstones D., Sleer L.S., Parton R.G., et al. Regulation of caveolin and caveolae by cholesterol in MDCK cells. J Lipid Res 1998, 39:369-379.
20. Frank P.G., Galbiati F., Volonte D., et al. Influence of caveolin-1 on cellular cholesterol efflux mediated by high-density lipoproteins. Am J Physiol Cell Physiol 2001, 280:C1204-C1214.
21. Smart E.J., Graf G.A., McNiven M.A., et al. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol 1999, 19:7289-7304.
22. Lisanti M.P., Scherer P.E., Tang Z., et al. Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis. Trends Cell Biol 1994, 4:231-235.
23. Razani B., Woodman S.E., Lisanti M.P. Caveolae: from cell biology to animal physiology. Pharmacol Rev 2002, 54:431-467.
24. Ostrom R.S., Gregorian C., Drenan R.M., et al. Receptor number and caveolar co-localization determine receptor coupling efficiency to adenylyl cyclase. J Biol Chem 2001, 276:42063-42069.
25. MacDougall D.A., Agarwal S.R., Stopford E.A., et al. Caveolae compartmentalise beta2-adrenoceptor signals by curtailing cAMP production and maintaining phosphatase activity in the sarcoplasmic reticulum of the adult ventricular myocyte. J Mol Cell Cardiol 2012, 52:388-400.
26. Pontier S.M., Percherancier Y., Galandrin S., et al. Cholesterol-dependent separation of the beta2-adrenergic receptor from its partners determines signaling efficacy: insight into nanoscale organization of signal transduction. J Biol Chem 2008, 283:24659-24672.
27. Ostrom R.S., Violin J.D., Coleman S., et al. Selective enhancement of beta-adrenergic receptor signaling by overexpression of adenylyl cyclase type 6: colocalization of receptor and adenylyl cyclase in caveolae of cardiac myocytes. Mol Pharmacol 2000, 57:1075-1079.
28. Ostrom R.S., Insel P.A. The evolving role of lipid rafts and caveolae in G protein-coupled receptor signaling: implications for molecular pharmacology. Br J Pharmacol 2004, 143:235-245.
29. Calaghan S., White E. Caveolae modulate excitation-contraction coupling and beta2-adrenergic signalling in adult rat ventricular myocytes. Cardiovasc Res 2006, 69:816-824.
30. Levitan I., Fang Y., Rosenhouse-Dantsker A., et al. Cholesterol and ion channels. Subcell Biochem 2010, 51:509-549.
31. Fang Y., Mohler E.R., Hsieh E., et al. Hypercholesterolemia suppresses inwardly rectifying K+ channels in aortic endothelium invitro and invivo. Circ Res 2006, 98:1064-1071.
32. Cox R.H., Tulenko T.N. Altered contractile and ion channel function in rabbit portal vein with dietary atherosclerosis. Am J Physiol 1995, 268:H2522-H2530.
33. Balijepalli R.C., Foell J.D., Hall D.D., et al. Localization of cardiac L-type Ca(2+) channels to a caveolar macromolecular signaling complex is required for beta(2)-adrenergic regulation. Proc Natl Acad Sci U S A 2006, 103:7500-7505.
34. Hoop C.L., Sivanandam V.N., Kodali R., et al. Structural characterization of the caveolin scaffolding domain in association with cholesterol-rich membranes. Biochemistry 2012, 51:90-99.
35. Cohen A.W., Hnasko R., Schubert W., et al. Role of caveolae and caveolins in health and disease. Physiol Rev 2004, 84:1341-1379.
36. Cohen A.W., Razani B., Wang X.B., et al. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol 2003, 285:C222-C235.
37. Santulli G., Lombardi A., Sorriento D., et al. Age-related impairment in insulin release: the essential role of beta(2)-adrenergic receptor. Diabetes 2012, 61:692-701.
38. Landry Y.D., Denis M., Nandi S., et al. ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J Biol Chem 2006, 281:36091-36101.
39. Mendez A.J., Lin G., Wade D.P., et al. Membrane lipid domains distinct from cholesterol/sphingomyelin-rich rafts are involved in the ABCA1-mediated lipid secretory pathway. J Biol Chem 2001, 276:3158-3166.
40. Gaus K., Gooding J.J., Dean R.T., et al. A kinetic model to evaluate cholesterol efflux from THP-1 macrophages to apolipoprotein A-1. Biochemistry 2001, 40:9363-9373.
41. Gaus K., Kritharides L., Schmitz G., et al. Apolipoprotein A-1 interaction with plasma membrane lipid rafts controls cholesterol export from macrophages. FASEB J 2004, 18:574-576.
42. Sorci-Thomas M.G., Owen J.S., Fulp B., et al. Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers. J Lipid Res 2012, 53:1890-1909.
43. Wei H., Averill M.M., McMillen T.S., et al. Modulation of adipose tissue lipolysis and body weight by high-density lipoproteins in mice. Nutr Diabetes 2014, 4:e108.
44. Hacker B.M., Tomlinson J.E., Wayman G.A., et al. Cloning, chromosomal mapping, and regulatory properties of the human type 9 adenylyl cyclase (ADCY9). Genomics 1998, 50:97-104.
45. Small K.M., Brown K.M., Theiss C.T., et al. An Ile to Met polymorphism in the catalytic domain of adenylyl cyclase type 9 confers reduced beta2-adrenergic receptor stimulation. Pharmacogenetics 2003, 13:535-541.
46. Kim S.H., Ye Y.M., Lee H.Y., et al. Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy. J Clin Pharm Ther 2011, 36:399-405.
47. Martinez F.D., Graves P.E., Baldini M., et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997, 100:3184-3188.
48. Drysdale C.M., McGraw D.W., Stack C.B., et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict invivo responsiveness. Proc Natl Acad Sci U S A 2000, 97:10483-10488.
49. Israel E., Drazen J.M., Liggett S.B., et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000, 162:75-80.
50. Taylor D.R., Drazen J.M., Herbison G.P., et al. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000, 55:762-767.
51. Ortega V.E., Meyers D.A., Bleecker E.R. Asthma pharmacogenetics and the development of genetic profiles for personalized medicine. Pharmacogenomics Person Med 2015, 8:9-22.
52. Hodges G.J., Gros R., Hegele R.A., et al. Increased blood pressure and hyperdynamic cardiovascular responses in carriers of a common hyperfunctional variant of adenylyl cyclase 6. J Pharmacol Exp Ther 2010, 335:451-457.
53. Maiga B., Dolo A., Toure O., et al. Human candidate polymorphisms in sympatric ethnic groups differing in malaria susceptibility in Mali. PLoS One 2013, 8:e75675.
54. Apinjoh T.O., nchang-Kimbi J.K., Njua-Yafi C., et al. Association of candidate gene polymorphisms and TGF-beta/IL-10 levels with malaria in three regions of Cameroon: a case-control study. Malar J 2014, 13:236.
55. Harrison T., Samuel B.U., Akompong T., et al. Erythrocyte G protein-coupled receptor signaling in malarial infection. Science 2003, 301:1734-1736.
56. Auburn S., Fry A.E., Clark T.G., et al. Further evidence supporting a role for Gs signal transduction in severe malaria pathogenesis. PLoS One 2010, 5:e10017.
57. Murphy S.C., Hiller N.L., Harrison T., et al. Lipid rafts and malaria parasite infection of erythrocytes. Mol Membr Biol 2006, 23:81-88.
58. Saadi A.V., Gupta H., Angural A., et al. Single nucleotide polymorphisms of ADRB2 gene and their association with susceptibility for Plasmodium falciparum malaria and asthma in an Indian population. Infect Genet Evol 2013, 20:140-147.
59. Flanagan J.M., Frohlich D.M., Howard T.A., et al. Genetic predictors for stroke in children with sickle cell anemia. Blood 2011, 117:6681-6684.
60. Sebastiani P., Ramoni M.F., Nolan V., et al. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005, 37:435-440.
61. Eyler C.E., Jackson T., Elliott L.E., et al. beta(2)-Adrenergic receptor and adenylate cyclase gene polymorphisms affect sickle red cell adhesion. Br J Haematol 2008, 141:105-108.
62. Hines P.C., Zen Q., Burney S.N., et al. Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. Blood 2003, 101:3281-3287.
63. Frank P.G., Lisanti M.P. Defining lipid raft structure and function with proximity imaging. Am J Physiol Heart Circ Physiol 2006, 290:H2165-H2166.
64. Berndt S.I., Gustafsson S., Magi R., et al. Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet 2013, 45:501-512.
65. Cherezov V., Rosenbaum D.M., Hanson M.A., et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318:1258-1265.
66. Hanson M.A., Cherezov V., Griffith M.T., et al. A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. Structure 2008, 16:897-905.
67. Kuschel M., Zhou Y.Y., Cheng H., et al. G(i) protein-mediated functional compartmentalization of cardiac beta(2)-adrenergic signaling. J Biol Chem 1999, 274:22048-22052.
68. Cang X., Du Y., Mao Y., et al. Mapping the functional binding sites of cholesterol in beta2-adrenergic receptor by long-time molecular dynamics simulations. J Phys Chem B 2013, 117:1085-1094.
69. Li X.M., Tang W.H., Mosior M.K., et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 2013, 33:1696-1705.
70. Garcia-Cardena G., Martasek P., Masters B.S., et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain invivo. J Biol Chem 1997, 272:25437-25440.
71. Michel J.B., Feron O., Sacks D., et al. Reciprocal regulation of endothelial nitric-oxide synthase by Ca2+-calmodulin and caveolin. J Biol Chem 1997, 272:15583-15586.
72. Drab M., Verkade P., Elger M., et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001, 293:2449-2452.
73. Banquet S., Delannoy E., Agouni A., et al. Role of G(i/o)-Src kinase-PI3K/Akt pathway and caveolin-1 in beta(2)-adrenoceptor coupling to endothelial NO synthase in mouse pulmonary artery. Cell Signal 2011, 23:1136-1143.
74. Leblais V., Delannoy E., Fresquet F., et al. beta-adrenergic relaxation in pulmonary arteries: preservation of the endothelial nitric oxide-dependent beta2 component in pulmonary hypertension. Cardiovasc Res 2008, 77:202-210.
75. Majmudar N.G., Anumba D., Robson S.C., et al. Contribution of nitric oxide to beta2-adrenoceptor mediated vasodilatation in human forearm arterial vasculature. Br J Clin Pharmacol 1999, 47:173-177.
76. Zeiher A.M., Drexler H., Wollschlaeger H., et al. Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. J Am Coll Cardiol 1989, 14:1181-1190.
77. Piscione F., Iaccarino G., Galasso G., et al. Effects of Ile164 polymorphism of beta2-adrenergic receptor gene on coronary artery disease. J Am Coll Cardiol 2008, 52:1381-1388.
78. Hesse C., Eisenach J.H. Genetic variation in the beta(2)-adrenergic receptor: impact on intermediate cardiovascular phenotypes. Curr Pharmacogenomics Person Med 2008, 6:160-170.
79. Monahan K.D., Feehan R.P., Sinoway L.I., et al. Contribution of sympathetic activation to coronary vasodilatation during the cold pressor test in healthy men: effect of ageing. J Physiol 2013, 591:2937-2947.
80. Barbato E., Piscione F., Bartunek J., et al. Role of beta2 adrenergic receptors in human atherosclerotic coronary arteries. Circulation 2005, 111:288-294.
81. Ferro A., Queen L.R., Priest R.M., et al. Activation of nitric oxide synthase by beta 2-adrenoceptors in human umbilical vein endothelium invitro. Br J Pharmacol 1999, 126:1872-1880.
82. Corbalán M.S., Marti A., Forga L., et al. Beta(2)-adrenergic receptor mutation and abdominal obesity risk: effect modification by gender and HDL-cholesterol. Eur J Nutr 2002, 41:114-118.
83. Large V., Hellstrom L., Reynisdottir S., et al. Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest 1997, 100:3005-3013.
84. Naka I., Hikami K., Nakayama K., et al. A functional SNP upstream of the beta-2 adrenergic receptor gene (ADRB2) is associated with obesity in Oceanic populations. Int J Obes (London) 2013, 37:1204-1210.
85. Sankaranarayanan S., de la Llera-Loya M., Drazul-Schrader D., et al. Importance of macrophage cholesterol content on the flux of cholesterol mass. J Lipid Res 2010, 51:3243-3249.
86. Epand R.M. Cholesterol and the interaction of proteins with membrane domains. Prog Lipid Res 2006, 45:279-294.
87. Niesor E.J., Chaput E., Mary J.L., et al. Effect of compounds affecting ABCA1 expression and CETP activity on the HDL pathway involved in intestinal absorption of lutein and zeaxanthin. Lipids 2014, 49:1233-1243.